Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
01 2022
Historique:
received: 25 01 2021
revised: 07 09 2021
accepted: 16 11 2021
pubmed: 25 11 2021
medline: 1 3 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

Cytotoxic T cell (CTL) infiltration of the tumor carries the potential to limit cancer progression, but their exclusion by the immunosuppressive tumor microenvironment hampers the efficiency of immunotherapy. Here, we show that expression of the axon guidance molecule Plexin-A4 (

Identifiants

pubmed: 34815265
pii: 2326-6066.CIR-21-0061
doi: 10.1158/2326-6066.CIR-21-0061
pmc: PMC7612191
mid: EMS140484
doi:

Substances chimiques

Nerve Tissue Proteins 0
Plxna4 protein, mouse 0
Programmed Cell Death 1 Receptor 0
Receptors, Cell Surface 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-141

Subventions

Organisme : European Research Council
ID : 773208
Pays : International

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

J Immunol. 2018 Aug 1;201(3):897-907
pubmed: 29898965
Oncogene. 2014 Oct 2;33(40):4795-802
pubmed: 24213581
Nat Med. 2010 Mar;16(3):339-45
pubmed: 20139992
Cancer Discov. 2014 May;4(5):522-6
pubmed: 24795012
Cancer Cell. 2013 Dec 9;24(6):695-709
pubmed: 24332039
Nat Rev Immunol. 2012 Sep;12(9):649-61
pubmed: 22918467
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
EMBO J. 2020 Jul 1;39(13):e102926
pubmed: 32500924
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
Blood. 2010 Dec 16;116(25):5536-47
pubmed: 20870900
Neuron. 2007 Feb 15;53(4):535-47
pubmed: 17296555
Immunity. 2011 Aug 26;35(2):161-8
pubmed: 21867926
J Immunol. 2008 Oct 1;181(7):4832-9
pubmed: 18802087
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268
pubmed: 31217020
Prog Biophys Mol Biol. 2015 Sep;118(3):161-8
pubmed: 25824683
Blood. 2011 Oct 13;118(15):4285-96
pubmed: 21832283
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Mech Dev. 2003 Mar;120(3):385-96
pubmed: 12591607
Oncogene. 2020 Jan;39(5):1080-1097
pubmed: 31591479
Neuron. 2005 Feb 17;45(4):513-23
pubmed: 15721238
Differentiation. 2012 Jan;83(1):77-91
pubmed: 22099179
Nat Cancer. 2020 Feb;1(2):210-221
pubmed: 32110781
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8865-E8874
pubmed: 28973925
Front Cell Neurosci. 2012 Jul 05;6:28
pubmed: 22783168
Eur J Immunol. 2005 Dec;35(12):3570-80
pubmed: 16285007
Nat Rev Immunol. 2013 Nov;13(11):802-14
pubmed: 24319778
EMBO J. 2010 Aug 4;29(15):2635-45
pubmed: 20606624
Sci STKE. 2002 Feb 12;2002(119):re1
pubmed: 11842242
J Neurobiol. 2004 Apr;59(1):24-33
pubmed: 15007824
Front Immunol. 2018 Nov 27;9:2737
pubmed: 30542345
Mol Ther. 2007 Dec;15(12):2063-9
pubmed: 17912237
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Bioessays. 2007 Apr;29(4):356-70
pubmed: 17373658
Genes Dev. 2002 Apr 1;16(7):836-45
pubmed: 11937491
J Cell Sci. 2009 Jun 1;122(Pt 11):1723-36
pubmed: 19461072
Lab Invest. 2017 Jun;97(6):669-697
pubmed: 28346400
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7087-E7096
pubmed: 27791111
Int Immunol. 2008 Mar;20(3):413-20
pubmed: 18209113
Nat Immunol. 2000 Oct;1(4):348-52
pubmed: 11017108
Sci Rep. 2019 Feb 13;9(1):1970
pubmed: 30760850
J Exp Med. 2010 Dec 20;207(13):2943-57
pubmed: 21098092
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
J Neurosci. 2010 May 19;30(20):7049-60
pubmed: 20484647
J Neurosci. 2005 Apr 6;25(14):3628-37
pubmed: 15814794
Semin Cancer Biol. 2018 Jun;50:13-20
pubmed: 29684436
Neuron. 2016 Aug 3;91(3):548-60
pubmed: 27397516
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Immunity. 2014 Nov 20;41(5):802-14
pubmed: 25464856
PLoS One. 2011;6(9):e24795
pubmed: 21966369
Nat Immunol. 2018 Jun;19(6):561-570
pubmed: 29777213
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Gut. 2016 Jun;65(6):990-1000
pubmed: 25814648
Cell Mol Life Sci. 2016 Apr;73(8):1609-22
pubmed: 26794845
Nat Rev Immunol. 2012 Nov;12(11):762-73
pubmed: 23018291

Auteurs

Ward Celus (W)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Ana I Oliveira (AI)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, University of Minho, Braga, Portugal.

Silvia Rivis (S)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Heleen H Van Acker (HH)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Ewout Landeloos (E)

Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.

Jens Serneels (J)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Sarah Trusso Cafarello (ST)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Yannick Van Herck (Y)

Department of General Medical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.

Roberta Mastrantonio (R)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.

Arnaud Köhler (A)

Institute for Medical Immunology, ULB-Center for Research in Immunology, Gosselies, Belgium.
Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.

Abhishek D Garg (AD)

Laboratory of Cell Stress & Immunity, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Véronique Flamand (V)

Institute for Medical Immunology, ULB-Center for Research in Immunology, Gosselies, Belgium.
Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.

Luca Tamagnone (L)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Jean-Christophe Marine (JC)

Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.

Mario Di Matteo (M)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Bruno M Costa (BM)

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, University of Minho, Braga, Portugal.

Oliver Bechter (O)

Department of General Medical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.

Massimiliano Mazzone (M)

Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium. massimiliano.mazzone@kuleuven.be.
Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH